VISTA, an AI-controlled data loop system, guides large-scale antibody design from scratch for applications in cancer therapy.

Latent Labs is backed by Radical Ventures, Sofinnova Partners, Google’s Chief Scientist Jeff Dean, Anthropic’s CEO Dario Amodei and Eleven Labs CEO Mati Staniszewski. About six months after coming out ...

Intranasal delivery of a monoclonal IgG1 antibody targeting mugwort pollen protected mice from allergic rhinitis and asthma ...

This research produced a highly-specific and sensitive anti-T-2 toxin monoclonal antibody (mAb), and developed a rapid and sensitive competitive indirect enzyme-linked immunosorbent assay (ELISA) ...

Organochlorine pollutants (OCPs), as a class of environmentally persistent and bioaccumulative toxic compounds, pose severe threats to ecosystems and human health. This study developed three novel ...

Traditional therapeutic antibody development has been constrained by long screening processes, and de novo antibody design requires a deep understanding of how the entire protein sequence affects ...

Chai Discovery, which builds frontier artificial intelligence to predict and reprogram the interactions between biochemical molecules, today announced a breakthrough in the de novo design of ...

Antibody-drug conjugates (ADCs) represent a mechanistically defined class of targeted therapeutics that combine monoclonal antibodies with cytotoxic payloads to achieve selective delivery to ...